Drug Pipeline Update
|
|
- Molly Porter
- 6 years ago
- Views:
Transcription
1 CLINICAL SOLUTIONS Drug Insights > September 2015 Drug Pipeline Update New Drug Information Synjardy (empagliflozin and metformin): Boehringer Ingelheim received Food and Drug Administration (FDA) approval for combination type 2 diabetes drug, Synjardy. The orally administered drug is a combination of the SGLT2-inhibitor Jardiance and metformin. Varubi (rolapitant): Tesaro obtained FDA approval for Varubi to be used in combination with other drugs to prevent and treat nausea and vomiting associated with chemotherapy. Varubi s mechanism of action is similar to Merck s Emend. Durlaza (aspirin, extended-release): New Haven Pharmaceuticals received FDA approval for their mg strength of aspirin for the secondary prevention of stroke and acute cardiac events such as myocardial infarction in high-risk patients. Durlaza will be available by prescription only. Vraylar (cariprazine): The FDA has approved Allergan s Vraylar for the treatment of adults with bipolar and schizophrenia. The FDA had previously rejected the application asking for more data. Generic Drug Information Xenazine (tetrabenazine): Two manufacturers have launched their generic version of Lundbeck s Xenazine for the treatment of chorea associated with Huntington s disease. Naprelan SR (naproxen SR 24hr): Generic versions of Almatica and Shionogi Pharma s Naprelan SR for the treatment of pain and other conditions are now available. According to IMS, Naprelan had approximately $58 million in annual U.S. sales. Atralin (tretinoin gel, 0.05%): Spear Dermatology Product has launched their generic equivalent of Valeant s Atralin for topical treatment of acne vulgaris. Exelon TD patch (rivastigmine TD patch): Sandoz has launched their generic version of Novartis Exelon patch for the treatment of Alzheimer s disease. According to IMS, Exelon had approximately $626 million in annual U.S. sales. While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.
2 Drug Insights > Drug Pipeline Update Page 2 New Molecular Entity Approvals in the Past Twelve Months Generic Name Brand Name Manufacturer Indication(s) Date Approved* cariprazine Vraylar Allergan Bipolar and schizophrenia September 2015 rolapitant Varubi Tesaro Prevention and treatment of chemotherapy induced nausea and vomiting flibanserin Addyi Sprout Pharmaceuticals Hypoactive sexual desire disorder (women) September 2015 August 2015 sacubitril/valsartan Entresto Novartis Heart failure July 2015 brexpiprazole Rexulti Otsuka/Lundbeck Schizophrenia/depression July 2015 eluxadoline Viberzi Actavis Irritable bowel syndrome with diarrhea ivabradine Corlanor Amgen Heart failure April 2015 isavuconazonium Cresemba Astellas Broad-spectrum azole antifungal March 2015 ceftazidine/avibactam Avycaz Actavis/AstraZeneca Bacterial infection February 2015 edoxaban Savaysa Daiichi Sankyo Anticoagulant January 2015 ceftolozane/tazobactam Zerbaxa Cubist Bacterial infection December 2014 peramivir Rapivab BioCryst Pharmaceuticals Viral infection December 2014 finafloxacin otic suspension Xtoro Alcon Acute otitis externa December 2014 palonosetron/netupitant Akynzeo Eisai Nausea and vomiting October 2014 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
3 Drug Insights > Drug Pipeline Update Page 3 Other New Product Approvals in the Past Twelve Months Generic Name Brand Name Manufacturer Indication(s) Date Approved* aspirin, extended-release Durlaza New Haven Pharmaceuticals Cardiovascular prevention September 2015 empagliflozin and metformin Synjardy Boehringer Ingelheim Diabetes August 2015 levetiracetam Spritam Aprecia Seizures August 2015 tacrolimus Envarsus XR Veloxis Pharma Prophylaxis of rejection in kidney transplant July 2015 doxycycline hyclate Targadox Journey Medical Corporation Treatment of various infections duloxetine 40 mg Irenka Lupin Pharmaceuticals Major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, chronic musculoskeletal pain olodaterol/tiotropium Stiolto Respimat Boehringer Ingelheim COPD May 2015 paliperidone palmitate Invega Trinza Johnson & Johnson Schizophrenia May 2015 codeine/chlorpheniramine Tuzistra XR Tris Pharma/Vernalis Cough and cold relief May 2015 albuterol Proair RespiClick Teva Asthma April 2015 levetiracetam extended-release tablets Elepsia XR Sun Pharmaceuticals Seizures March 2015 levonorgestrel Liletta Actavis/Medicines 360 Contraception (intrauterine) February 2015 insulin U-300 Toujeo Sanofi Diabetes February 2015 olopatadine ophthalmic solution Pazeo Alcon Ocular allergies February 2015 empagliflozin/linagliptin Glyxambi Boehringer Ingelheim/ Eli Lilly Diabetes January 2015 hydrocodone ER Zohydro ER Zogenix Pain January 2015 perindopril and amlodpine Prestalia Symplmed Pharmaceuticals High blood pressure January 2015 carbidopa/levodopa enteral suspension carbidopa/levodopa extended release Duopa AbbVie Parkinson s disease January 2015 Rytary Impax Laboratories Parkinson s disease January 2015 ivermectin cream 1% Soolontra Galderma Rosacea January 2015 memantine extended release/ donepezil Namzaric Forest Alzheimer s disease January 2015 liraglutide 3 mg Saxenda Novo Nordisk Obesity December 2014 hydrocodone ER Hysingla ER Purdue Pain November 2014 dapagliflozin/metformin Xigduo XR AstraZeneca Diabetes November 2014 budesonide foam Uceris Salix Ulcerative colitis October 2014 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
4 Drug Insights > Drug Pipeline Update Page 4 Pipeline Watch Generic Name Brand Name Manufacturer Indication(s) Anticipated FDA Decision Date codeine/chlorpheniramine Rinotuss 12 Spriaso/NexGen Cough and cold relief Summer 2015 saxagliptin/dapagliflozin N/A AstraZeneca Diabetes 4Q 2015 morphine ER MorphaBond ER Inspirion Delivery Pain (abuse deterrent) September 2015 aripiprazole lauroxil Aristada Alkermes Schizophrenia October 2015 oxycodone, extended-release Xtampeza Collegium Pharmaceuticals Pain (abuse deterrent) October 2015 hydrocodone ER N/A Teva Pain (abuse deterrent) October 2015 oxycodone IR Avridi Purdue Pain (abuse deterrent) October 2015 buprenorphine buccal film Belbuca Endo, Biodelivery Sciences Pain October 2015 oxycodone/naltrexone ER N/A Pfizer Pain (abuse deterrent) October 2015 amphetamine Dynavel XR Tris Pharma ADHD October 2015 insulin degludec/insulin aspart Ryzodeg NovoNordisk Diabetes October 2015 insulin degludec Tresiba NovoNordisk Diabetes October 2015 patiromer N/A Relypsa High potassium October 2015 lifitegrast N/A Shire Dry eye disease October 2015 brivaracetam N/A UCB Pharma Seizures November 2015 meloxicam N/A Iroko Pain November 2015 sumatriptan, intranasal powder N/A Avanir Migraine November 2015 methylphenidate ER, ODT calcipotriene/betamethasone, aerosol foam Cotempla XR-ODT Neos Therapeutics ADHD November 2015 N/A Leo Pharma Plaque psoriasis November 2015 naloxone nasal spray N/A Indivior, AntiOp Treatment of opioid overdose November 2015 enclomiphene N/A Repros Low testosterone November 2015 glycopyrronium N/A Novartis COPD December 2015 glycopyrronium/indacaterol N/A Novartis COPD December 2015 lesinurad N/A AstraZeneca Gout December 2015 safinamide Xadago Newron Pharmaceuticals Parkinson s disease December 2015
5 Drug Insights > Drug Pipeline Update Page 5 First Generic Approvals of Top Selling Brand Name Drugs in the Past Twelve Months Generic Name Brand Name Brand Manufacturer Indication(s) Date Approved* memantine Namenda Actavis Alzheimer s disease July 2015 glatiramer Glatopa Teva Relapsing-remitting multiple sclerosis aripiprazole Abilify Bristol-Myers Squibb Schizophrenia, bipolar disorder and Tourette s syndrome May 2015 esomeprazole Nexium AstraZeneca Gastrointestinal disorders (PPI) February 2015 celecoxib Celebrex Pfizer Pain December 2014 valganciclovir Valcyte Genentech Viral infections November 2014 * Date usually indicates FDA approval date. The product s launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market.
6 Drug Insights > Drug Pipeline Update Page 6 Other First Generic Approvals in the Past Twelve Months Generic Name Brand Name Brand Manufacturer Indication(s) Date Approved* rivastigmine TD patch Exelon TD patch Novartis Alzheimer s disease September 2015 tretinoin gel, 0.05% Atralin Valeant Acne September 2015 naproxen SR 24hr Naprelan SR Almatica and Shionogi Pharma tetrabenazine Xenazine Lundbeck Chorea associated with Huntington s disease Pain September 2015 August 2015 pramipexole extended-release Mirapex Boehringer Ingelheim Parkinson s disease August 2015 phenoxybenzamine Dibenzyline Concordia Pheochromocytoma August 2015 acetaminophen/caffeine/dihydrocodeine Trezix Wraser Pharmaceuticals Pain August 2015 megestrol acetate suspension Megace ES Par Loss of appetite August 2015 budesonide inhalation susp, 1 mg/2 ml Pulmicort Respules AstraZeneca Respiratory August 2015 almotriptan Axert Jannsen Migraine July 2015 pyridostigmine bromide Mestinon Timespan Valeant Myasthenia gravis July 2015 bexarotene Targretin Valeant Cutaneous T-cell lymphoma July 2015 alosetron Lotronex Prometheus Irritable bowel syndrome with diarrhea naftifine cream, 1% Naftin Merz Fungal infections (topical) risedronate Actonel Actavis Osteoporosis norethindrone/ethinyl estradiol Femhrt Actavis Menopause symptoms May 2015 tolcapone Tasmar Valeant Parkinson s disease May 2015 benzonatate Zonatuss Vertical Relief of cough May 2015 metoclopramide ODT Metozolv ODT Salix Relief of GERD April 2015 norethindrone/ethinyl estradiol/fe Generess FE Warner Chilcott Contraception (oral) April 2015 naproxen sustained- release Naprelan Almatica Pain March 2015 methylphenidate chewable tabs Methylin Shionogi Pharma ADHD March 2015 pramipexole Mirapex ER Boehringer Ingelheim Parkinson s disease February 2015 clobetasol spray, 0.05% Clobex spray Galderma Psoriasis January 2015 estradiol TD patch Vivelle Dot Novartis Vasomotor symptoms January 2015 guanfacine Intuniv Shire ADHD December 2014 urea cream Keralac Brava Pharmaceuticals Dry skin conditions December 2014 sulfacetamide sodium/sulfur liquid, cream and lotion Plexion Brava Pharmaceuticals Acne December 2014 tacrolimus ointment Protopic Astellas Atopic dermatitis December 2014 sirolimus Rapamune Pfizer Prevention of transplant rejection ivermectin Stromectol Merck Parasitic roundworm infections November 2014 November 2014 norethindrone/ethinyl estradiol/fe Loestrin 24 FE Actavis Contraception (oral) November 2014
7 Drug Insights > Drug Pipeline Update Page 7 Other First Generic Approvals in the Past Twelve Months continued Generic Name Brand Name Brand Manufacturer Indication(s) Date Approved* olopatadine nasal solution Patanase Alcon Allergic rhinitis November 2014 mycophenolate Cellcept suspension Genentech Prevention of transplant rejection November 2014 amlodipine, valsartan Exforge Novartis High blood pressure October 2014 *Date usually indicates FDA approval date. The product s launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market. Generics of Top Selling Brand Drugs Potentially Available Soon Generic Name Brand Name Brand Manufacturer Indication(s) To Market Date* aprepitant Emend Merck Nausea and vomiting 4Q 2015 dutasteride Avodart GlaxoSmithKline Benign prostatic hyperplasia (BPH) 4Q 2015 palonosetron Aloxi (capsule) Eisai Nausea and vomiting October 2015 *Expected to market dates are predictions made by Prime Therapeutics based on industry information A1 Prime Therapeutics LLC 09/15
Drug Pipeline Update
CLINICAL SOLUTIONS Drug Insights > December 2015 Drug Pipeline Update New Drug Information Narcan (naloxone): Adapt Pharma and Lightlake Therapeutics received Food and Drug Administration (FDA) approval
More informationMedicare Part D 2016 Formulary Changes Desert Preferred Choice
Medicare Part D 2016 Formulary s Desert Preferred Choice Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
More informationAetna Better Health Illinois Premier Plan. November 2015 Formulary Updates. October 2015 Formulary Updates
Aetna Better Health Illinois Premier Plan November 2015 Formulary Updates desogestrel & ethinyl estradiol tab 0.15 mg-30 mcg RIVASTIGMINE DIS 13.3/24; QL (30 patches/30 days) RIVASTIGMINE DIS 4.6MG/24;
More informationRationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)
BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2015 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 19, 2015 The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of
More informationTable 1. New drugs approved by the US Food and Drug Administration (FDA): December 13, 2014 through January 18, 2015
Hosp Pharm 2015;50(3):238 242 2015 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5003-238 Current FDA-Related Drug Information Approvals, Submission, and Important Labeling Changes
More informationFormulary Change Notice
Formulary Change Notice HealthPartners may remove drugs from our formulary (list of covered drugs) or add rules about whether and when certain drugs are covered during the year. The chart below contains
More informationNew Generics: Specialty Network: Retail Pharmacies Dispensing Specialty Products
SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE JANUARY 2016 ISSUE 1 HELPFUL NUMBERS FOR PROVIDERS Magellan: 1-800-846-7971 Bin: 016523 Processor control: 747 HELPFUL NUMBERS
More informationMedicare Part D 2016 Formulary Changes Service To Senior and OC Preferred
Medicare Part D 2016 Formulary s Service To Senior and OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior
More informationStep Therapy Requirements. Effective: 12/01/2016
Effective: 12/01/2016 H2986_PD_049 Updated 11/2016 ALPHA 1-PROTEINASE INHIBITOR GLASSIA PRIOR CLAIM FOR ARALAST NP OR ZEMAIRA WITHIN THE PAST 120 DAYS. ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See Below BY Drug List (PDL) Update January 20, 2016 Pharmacy Services Leesa M. Allen, Deputy Secretary Office of
More informationPharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017
Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
More informationStep Therapy Group. Atypical Antipsychotic Agents
Atypical Antipsychotic Agents Any beneficiary newly enrolled into Community Care, Inc. currently receiving aripiprazole, aripiprazole ODT, risperidone, risperidone ODT, olanzapine, olanzapine ODT, quetiapine,
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Summary of change: The Pharmacy and Therapeutics Committee (P&T) reviewed and approved the formulary changes listed in the table below on March 29, 2016. What
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
More informationMedicare Part D 2016 Formulary Changes Service To Senior and OC Preferred
Medicare Part D 2016 Formulary s Service To Senior and OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: The formulary changes listed in the table below were reviewed and approved at our second quarter 2018, Pharmacy and Therapeutics Committee
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationScope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 24, 2016 Summary of change The Pharmacy and Therapeutics Committee reviewed and approved the formulary changes listed in the table below on March 29, 2016. What this means to you
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationUpdates to your prescription benefits Effective July 1, 2016 for your Advantage Prescription Drug List
Updates to your prescription benefits Effective July 1, 2016 for your Advantage Prescription Drug List Please review the following updates These will affect your Prescription Drug List (PDL) as of July
More informationMichigan Department of Health and Human Services Pharmacy and Therapeutics Committee
Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee June 14, 2016 Minutes Final Attendee: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr.
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationWellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/03/2015.
More informationVNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED
More informationNew Drug Update 2016: Community Focus Brooke McComb, PharmD
New Drug Update 2016: Community Focus Brooke McComb, PharmD Objectives: 1. Identify significant therapeutic agents that were granted U.S. Food and Drug Administration approval in the past year 2. Describe
More informationLIST OF DRUGS DURING 2004
LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004
More informationAlzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationVNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017
Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA
More informationALLERGIC CONJUNCTIVITIS AGENTS
2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops
More informationQuarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationSOLID DOSAGE FORMULATIONS
SOLID DOSAGE FORMULATIONS Jubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across
More informationAdvanced Control Formulary Change Summary Report Effective
This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary. ADDITIONS: Brand Agents: Ajovy (fremanezumabvfrm) subcutaneous injection Aristada
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationManaging the Unmanageable
Managing the Unmanageable Controlling Costs in an Explosive Rx Environment Presented by: Dick Bullard, RPh, SVP Pharmacy Darryl Martin, VP of Sales A Unique Vision of Care Magellan Health is a healthcare
More informationANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY
South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More information2017 Step Therapy Criteria
FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.
More informationUPDATE WellCare s South Carolina
September 3, 2015 UPDATE WellCare s South Carolina Preferred Drug List Dear Provider: At the September 3, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes
More informationStep Therapy Requirements. Effective: 05/01/2018
Step Therapy Requirements Effective: 05/01/2018 ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationNeighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
More informationYour prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
More informationANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria
ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet
More informationStep Therapy Requirements. Effective: 11/01/2018
Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
More information2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationAdvanced Control Formulary Change Summary Report Effective
This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary. ADDITIONS: Brand Agents: Mepron (atovaquone) suspension Mydayis (amphetaminedextroamphetamine)
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: February 15, 2018. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationBLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500
More informationNew Exception Status Benefits
AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)
More informationMerrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc
Merrill Lynch Global Healthcare Conference February 4, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 995 The statements
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationR&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
More informationDepression Disease Market and Forecast Analysis 2024 Report Extract
Datamonitor Healthcare Pharma intelligence Depression Disease Market and Forecast Analysis 2024 Report Extract Find out more about the full report Contents (for full report) 10 FORECAST: DEPRESSION (Published
More informationUPDATE Ohana QUEST Integration Medicaid
UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes
More informationAcyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationMichigan Pharmacy and Therapeutics Committee
Michigan Pharmacy and Therapeutics Committee June 14, 2016 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: I. Introductions II. Conflict of Interest Statement III. Approval of the Agenda IV.
More informationDiagnostic and Pharmaceutical News for You and Your Medical Practice
15MS3092 BioTherapeutics Q u a r t e r l y Diagnostic and Pharmaceutical News for You and Your Medical Practice Volume 20/Summer 2015 Illustration: Human Liver BQ BioTherapeutics 2 BQ BioTherapeutics Q
More informationANTIDIABETIC AGENTS - MISCELLANEOUS
ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG,
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
More informationR&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Age Edits Rx.01.2 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications
More informationFormulary Medical Necessity Program
BENEFIT APPLICATION Formulary Medical Necessity Program DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationTABLE OF CONTENTS. 4. Formulation Opportunities Oral Reformulation Taste Masking MCD GROUP, LLC October
TABLE OF CONTENTS 1. Executive Summary... 9 Market Overview... 9 Drug Delivery Systems for Pediatrics... 10 Formulation Opportunities... 10 Specialty Pediatric Companies... 11 Product Licensing Opportunities...
More informationAMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationNetwork Health Insurance Corporation Upcoming Negative Changes to the Medicare Part D Formulary
Requesting an Exception to the Formulary You can ask Network Health Insurance Corporation to make an exception to our coverage rules. Generally, we will only approve your request for an exception if alternative
More informationDrug Formulary Update, October 2016 Commercial and State Programs
Drug Formulary Update, October 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationStep Therapy Requirements
Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationWell Informed. A Comprehensive Approach to Pain Management. Pain Guardian
Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid
More informationDrug Formulary Update, January 2017 Commercial and State Programs
Drug Formulary Update, January 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationACYCLOVIR OINT (CCHP2017)
ACYCLOVIR OINT (CCHP2017) acyclovir 5 % topical ointment Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir. 1 ALPHAGAN
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationStep Therapy Requirements. Effective: 1/1/2019
Effective: 1/1/2019 Updated 1/2019 AMANTADINE ER Sharp Health Plan (HMO) OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More information